Literature DB >> 12107853

Heart-rate variability (HRV) in the ECG trace of routine EEGs: fast monitoring for the anticholinergic effects of clozapine and olanzapine?

G W Eschweiler1, M Bartels, G Längle, B Wild, I Gaertner, M Nickola.   

Abstract

Drug monitoring in psychiatry usually serves psychoactive drug plasma concentration measurement. Anticholinergic properties offer a faster approach to monitoring pharmacodynamic intraindividual effects of the drug by measuring their effects on heart rate variability (HRV), which is sympathetically and parasympathetically controlled via cholinergic synapses. The plasma concentrations of the atypical antipsychotics clozapine and olanzapine correlated with parameters of HRV in 59 patients suffering from schizophrenia or schizoaffective disorder. HRV during 4 minutes at rest was extracted from the ECG trace of a routine digital EEG registration in addition to blood sampling for plasma concentration measurement (HPLC method). We calculated sympathetically and parasympathetically controlled heart frequency bands (low, medium and high frequency) and other HRV parameters, coefficient of variation (CV), and root mean square of successive differences (RMSSD). All HRV parameters were significantly more impaired in clozapine patients (n = 33, mean clozapine plasma concentration 331 +/- 294 ng/ml) than in olanzapine patients (n = 26, mean olanzapine plasma concentration 42 +/- 32 ng/ml) and demonstrated 1.7 - 4.8 times the cardiac anticholinergic properties of clozapine in vivo. 14 out of 14 patients with a CV beyond 3.2 % had clozapine plasma concentrations below the proposed optimal therapeutic concentration of 350 ng/ml. All HRV parameters were inversely and significantly correlated with the clozapine plasma concentrations (such as lgCV: r = - 0.73, p < 0.001) and, to a lesser extent, with the olanzapine plasma concentrations (lgCV r = - 0.44, p < 0.05). These results underline the potential clinical value of HRV parameter extraction from routine ECGs in predicting plasma concentrations and objective individual neurocardiac effects of drugs with anticholinergic properties.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12107853     DOI: 10.1055/s-2002-31520

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  6 in total

1.  Cardiac risk and schizophrenia.

Authors:  Ripu Jindal; Erin M MacKenzie; Glen B Baker; Vikram K Yeragani
Journal:  J Psychiatry Neurosci       Date:  2005-11       Impact factor: 6.186

Review 2.  Classifying antipsychotic agents : need for new terminology.

Authors:  Ripu D Jindal; Matcheri S Keshavan
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 3.  A systematic review and meta-analysis of the association between clozapine and norclozapine serum levels and peripheral adverse drug reactions.

Authors:  Madeleine S A Tan; Faraz Honarparvar; James R Falconer; Harendra S Parekh; Preeti Pandey; Dan J Siskind
Journal:  Psychopharmacology (Berl)       Date:  2021-01-07       Impact factor: 4.530

4.  The pNNx Heart Rate Variability Statistics: An Application to Neuroautonomic Dysfunction of Clozapine-Treated Subjects.

Authors:  Jong-Hoon Kim; Sang Hoon Yi; Yong Min Ahn; Kyu Young Lee; Seung Ae Yang; Yong Sik Kim
Journal:  Psychiatry Investig       Date:  2009-11-09       Impact factor: 2.505

5.  Beat-to-beat heart rate and QT interval variability in first episode neuroleptic-naive psychosis.

Authors:  Ripu D Jindal; Matcheri S Keshavan; Kevin Eklund; Angela Stevens; Debra M Montrose; Vikram K Yeragani
Journal:  Schizophr Res       Date:  2009-07-01       Impact factor: 4.939

Review 6.  Adverse Drug Reactions in Relation to Clozapine Plasma Levels: A Systematic Review.

Authors:  Maria Skokou; Eleni A Karavia; Zoi Drakou; Vassiliki Konstantinopoulou; Christina-Anna Kavakioti; Philippos Gourzis; Kyriakos E Kypreos; Ourania Andreopoulou
Journal:  Pharmaceuticals (Basel)       Date:  2022-07-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.